These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19933078)

  • 1. Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories.
    Blancas I; Gómez FJ; Bermejo B; Hennessy BT; Chirivella I; Magro A; Caballero A; Ferrer J; Valero V; Lluch A
    Clin Breast Cancer; 2009 Nov; 9(4):231-6. PubMed ID: 19933078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.
    Sun JM; Han W; Im SA; Kim TY; Park IA; Noh DY; Heo DS; Bang YJ; Choe KJ; Kim NK
    Cancer; 2004 Dec; 101(11):2516-22. PubMed ID: 15517588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy.
    Boyages J; Chua B; Taylor R; Bilous M; Salisbury E; Wilcken N; Ung O
    Br J Surg; 2002 Jun; 89(6):789-96. PubMed ID: 12027994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of breast conservation therapy for breast cancer in Hong Kong: prognostic impact of ipsilateral breast tumor recurrence and 2005 St. Gallen risk categories.
    Yau TK; Soong IS; Chan K; Chan M; Cheung P; Lau HW; Chang AT; Lee AW
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):667-72. PubMed ID: 17379441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial.
    Schmidt M; Victor A; Bratzel D; Boehm D; Cotarelo C; Lebrecht A; Siggelkow W; Hengstler JG; Elsässer A; Gehrmann M; Lehr HA; Koelbl H; von Minckwitz G; Harbeck N; Thomssen C
    Ann Oncol; 2009 Feb; 20(2):258-64. PubMed ID: 18824499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer.
    Jung SY; Han W; Lee JW; Ko E; Kim E; Yu JH; Moon HG; Park IA; Oh DY; Im SA; Kim TY; Hwang KT; Kim SW; Noh DY
    Ann Surg Oncol; 2009 May; 16(5):1112-21. PubMed ID: 19219507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies.
    Chia SK; Speers CH; Bryce CJ; Hayes MM; Olivotto IA
    J Clin Oncol; 2004 May; 22(9):1630-7. PubMed ID: 15117985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of St Gallen risk categories in prognostication of breast cancer patients in Southern Sri Lanka.
    Peiris H; Mudduwa L; Thalagala N; Jayatilake K
    BMC Womens Health; 2018 Jan; 18(1):30. PubMed ID: 29385991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy.
    Garassino I; Gullo G; Orefice S; Tondulli L; Masci G; Salvini P; Eboli M; Di Tommaso L; Giordano L; Alloisio M; Roncalli M; Santoro A
    Breast; 2009 Aug; 18(4):263-6. PubMed ID: 19682903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the prognostic value of 2005 St Gallen risk categories for operated breast cancers in Hong Kong.
    Yau TK; Soong IS; Chan K; Chang A; Sze H; Yeung MW; Tung R; Lau S; Lee A
    Breast; 2008 Feb; 17(1):58-63. PubMed ID: 17804235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor.
    Blancas I; García-Puche JL; Bermejo B; Hanrahan EO; Monteagudo C; Martínez-Agulló A; Rouzier R; Hennessy BT; Valero V; Lluch A
    Ann Oncol; 2006 Nov; 17(11):1644-9. PubMed ID: 16873428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Yovino S; Kwok Y; Krasna M; Bangalore M; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1438-43. PubMed ID: 16029805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
    Kaplan HG; Malmgren JA; Atwood M
    Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.